Immune Cell Function Assay
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Oklahoma Policy CPCPLAB028 alerts
Get alerted when Policy CPCPLAB028 changes without checking for updates manually.
Monitor payer policy activity
Policy governing reimbursement and use of immune cell function assays for monitoring and predicting immune function primarily after solid organ transplantation for Blue Cross Blue Shield - Oklahoma members and providers.
No material clinical or coverage changes in this revision.
Coverage Criteria for Immune Cell Function Assay
Reimbursable Indication
Covered when the following condition is met
Plan documents and product-specific criteria apply; not all products or indications are covered.
An immune cell function assay is not reimbursable for many clinical uses. Excluded indications include, but are not limited to: management of autologous or allogeneic hematopoietic stem cell transplantation; management of immunodeficiency disorders including human immunodeficiency virus (HIV) and severe combined immunodeficiency disease (SCID); management of or prediction of infection risk in immune-mediated disorders such as rheumatoid arthritis, multiple sclerosis, and lupus nephritis; testing for urticaria; diagnosis and management of Lyme disease (for example, iSpot Lyme Test); management of inflammatory bowel diseases; and monitoring immune response following surgery.
Per this policy, use of an immune cell function assay outside the context of monitoring or predicting immune function after solid organ transplantation is not supported and is therefore not reimbursable for the many indications listed in the exclusions. Providers should rely on the plan’s specific coverage criteria for situations that might differ from the excluded indications.
Coding and Procedure Codes
Provider Actions, Documentation, and Billing
Plan-dependent prior authorization
Not all lab management reimbursement criteria apply to every product. Providers must review the member's Plan documents (Certificates of Benefits, benefit booklets, Summary Plan Descriptions, or other coverage documents) to determine whether coverage and any prior authorization requirements apply for immune cell function assays for that specific product.
Confirm product-specific coverage before ordering
Use immune cell function assays for monitoring and predicting immune function after solid organ transplantation only when plan documents indicate coverage; providers should confirm product-specific eligibility before ordering.
Documentation and coding requirements
Providers must submit accurate documentation of services performed and code claims using valid HIPAA-approved code sets and industry-standard coding guidelines; be prepared to provide additional documentation upon request.
- Use valid code combinations from HIPAA-approved code sets (CPT, HCPCS, ICD-10-CM/PCS, NDCs, DRG guidance).
- Code claims according to industry standards (Uniform Billing Editor, AMA CPT guidance, CMS NCCI edits, CCI table edits).
- Submit additional documentation if requested during claim review.
Claims and documentation risk
Claims are subject to code-edit protocols, medical policy review, plan and provider contract terms; incomplete or inaccurate documentation or coding may result in claim denial.
- Claim submissions may be reviewed against benefit coverage, provider contract language, medical policies, and coding software logic.
- Failure to provide requested documentation or to code appropriately can lead to denial.
Background and Rationale
Immune cell function assays are laboratory tests intended to measure aspects of cell‑mediated immune response and have been studied as tools to predict infection and rejection risk in solid organ transplant recipients. The policy identifies monitoring and predicting immune function after solid organ transplantation as the primary potentially reimbursable clinical use, while noting that evidence does not support reimbursement for a range of other clinical contexts (see exclusions).
Definitions
Candidate Criteria for Testing
Solid Organ Transplant Monitoring
Transplant-specific reimbursable context
Policy refers broadly to solid organ transplantation without organ-type specific criteria.
Post-Transplant Coverage Considerations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.